Skip to main content
. 2018 Apr 16;2(8):848–858. doi: 10.1182/bloodadvances.2018017517

Figure 3.

Figure 3.

IMGN632 displays preferential killing of leukemic over normal progenitors. Bone marrow mononuclear cells from 15 AML patients and 11 healthy donors were treated with serial dilutions of IMGN632 and GO for 20 hours, followed by CFU assay. The ADC concentrations that kill 90% of the cells are presented. Horizontal bars indicate median value for the sample set.